Fapeng Zhang
Guangzhou, 510120, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The allosteric IDH1 inhibitor ivosidenib overcomes chemoresistance in intrahepatic cholangiocarcinoma models expressing wild-type IDH1.
Journal: The Journal of clinical investigation
Published: August 29, 2025
Immune checkpoint inhibitor-related T-cell-mediated rejection increases the risk of perioperative graft loss after liver transplantation.
Journal: Chinese medical journal
Published: March 09, 2025
Tumor necrosis facilitates perihilar cholangiocarcinoma metastasis by ANGPTL6-augmented vessel permeability and tumor dissemination.
Journal: JHEP reports : innovation in hepatology
Published: February 14, 2025
Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation.
Journal: Cancer immunology, immunotherapy : CII
Published: July 01, 2024
Oleic acid-PPARγ-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment.
Journal: Hepatology (Baltimore, Md.)
Published: August 06, 2023
Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models.
Journal: The Journal of clinical investigation
Published: July 06, 2022
Bioinformatic Analysis and In Vitro and In Vivo Experiments Reveal That Fibrillarin Participates in the Promotion of Lung Metastasis in Hepatocellular Carcinoma.
Journal: Bioengineering (Basel, Switzerland)
Published: June 23, 2022
Hepatitis B Virus Promotes Hepatocellular Carcinoma Progression Synergistically With Hepatic Stellate Cells via Facilitating the Expression and Secretion of ENPP2.
Journal: Frontiers in molecular biosciences
Published: July 23, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026